evidence: After neoadjuvant chemotherapy, the patients treated with the TEL chemotherapy regimen showed a TpCR rate of 38.7% (24/62), whereas the patients who were treated with the TE regimen showed a TpCR rate of 12.7% (8/63) (odds ratio (OR), 4.342, 95% CI 1.764–10.687; P = 0.001; Fig. 2).
intervention:   docetaxel (T) and epirubicin (E) +  lobaplatin (L)
comparator:  docetaxel (T) and epirubicin (E)
outcome: Pathologic CR in the breast and the axilla (TpCR)